A new study in Nucleic Acids Research, published by Oxford University Press, suggests a possible effective treatment strategy for patients suffering from prion disease.
Prion disease is a rapidly fatal and currently untreatable neurodegenerative disease. While prion disease is quite rare, it typically causes rapid neurodegeneration. About 300 cases of prion diseases are reported each year in the United States. The most common form of prion disease that affects humans is Creutzfeldt-Jakob disease. Bovine spongiform encephalopathy, popularly known as Mad Cow Disease, is another prion disease. Prion diseases are caused by disrupting the structure of a normal human prion protein, producing toxic clumps in the brain. Because prion protein is central to disease, reducing levels of prion protein in patients is a promising therapeutic approach.
Senior author Sonia Vallabh learned that she carried a mutant form of the prion protein gene prior to switching careers to become a patient-scientist and advocate for treatment. She and her coworkers had previously observed that antisense oligonucleotides that reduce levels of prion protein can extend the survival of animals infected with misfolded prions. While these initial data were promising, many critical questions remained before therapeutic development could be possible.
Research teams led by Vallabh at the Broad Institute of Harvard and MIT, Holly Kordasiewicz at Ionis Pharmaceuticals, and Deb Cabin at McLaughlin Research Institute, report the results of preclinical studies of an antisense therapy against prion disease. In this new work, using an expanded set of prion protein -targeting antisense oligonucleotides, the authors have laid the basis for full scale clinical development. This research shows that, across multiple treatment paradigms, reducing levels of prion protein in prion-infected lab animals significantly extends their survival.
Researchers here showed that reducing levels of prion protein can triple the survival of prion-infected animals. Even reducing prion protein levels by a small amount, which should be easier to achieve clinically, resulted in significant survival benefits.
Reduction of prion protein is effective across prion strains and across a battery of different treatment timepoints. The researchers show that reducing prion protein is effective before any symptoms are seen. They also demonstrate, for the first time, that a single dose of a prion protein -lowering treatment can reverse markers of disease even after toxic clumps have formed in the brain.
“While there are still many steps ahead,” said Vallabh, “these data give us optimism that by aiming straight at the genetic heart of prion disease, genetically targeted drugs designed to lower prion protein levels in the brain may prove effective in the clinic.”
The article, “Prion Protein Lowering is a Disease-modifying Therapy Across Prion Strains, Stages, and Endpoints” is available to the public on August 10th.
Direct correspondence to:
Sonia M Vallabh
Stanley Center for Psychiatric Research
Broad Institute of MIT and Harvard
415 Main St.
Cambridge, MA 02142
To request a copy of the study, please contact:
Funding: Studies at the Broad Institute were supported by the Next Generation Fund at the Broad Institute of MIT and Harvard, Prion Alliance, direct donations to Prions@Broad, the National Institutes of Health (F31 AI122592), the National Science Foundation (GRFP 2015214731), and an anonymous organization. Studies at McLaughlin Research Institute were supported by Prion Alliance and Ionis Pharmaceuticals. Studies at Ionis Pharmaceuticals were funded by Ionis Pharmaceuticals.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.